Trail against hyperlipidemia Patients with high risks to Investigate the effect ON small dense ldl & idl by using middlE dosE rosuvastatin, atrovastatin, psSk-9 inhibitor(relationship of blood ANGPTL, Sortilin, miRNA and so on level) (PIONEERs in Saitama Study 3)

Trail against hyperlipidemia Patients with high risks to Investigate the effect ON small dense ldl & idl by using middlE dosE rosuvastatin, atrovastatin, psSk-9 inhibitor(relationship of blood ANGPTL, Sortilin, miRNA and so on level) (PIONEERs in Saitama Study 3) - PIONEERs Study 3

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018818

Enrollment

300

Registered

2015-09-14

Start date

2025-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Interventions

Rosuvastatin group: start from rosuvastatin 5mg, increased to 20mg, Atorvastatin group: start from atorvastatin 10mg, increased to 40mg Statin and evolocumab combination group: combination therap

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)-4) 4 examine group 1)T2DM with 70 mg/dl or more than 70 mg/dl LDL-C 2)Patients of JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 CategoryIII (Diabetes patients are excepted) with 70 mg/dl or more than 70 mg/dl LDL-C 3)Patients of JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 Secondary prevention with 100 mg/dl or more than 100 mg/dl LDL-C 4)statin intolerance patients

Exclusion criteria

Exclusion criteria: patients considered as inadequated by the investigator and doctor

Design outcomes

Primary

Measure	Time frame
Lipid profile (TC,TG,HDL-C, Friedewald LDL-C, small dense LDL,IDL), apo protein, apoE phenotype Lp(a), dementia/cognitive function after 6 months, 12 months, 2 years, 3 years, 4 years, 5 years to treatment	—

Secondary

Measure	Time frame
The CAC scoring (Agatston Units, AUs) and stenosis and the event rate of cerebrovascular and cardiovascular disease, blood ANGPTL, Sortilin, miRNA and so on level after 6 months, 12 months, 2 years, 3 years, 4 years, 5 years treatment	—

Countries

Japan

Contacts

Public ContactIkuo Ikuo Inoue

Saitama Medical University Dept. of Endocrinology and Diabetology

i1901018@saitama-med.ac.jp049-276-1875

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Trail against hyperlipidemia Patients with high risks to Investigate the effect ON small dense ldl &amp; idl by using middlE dosE rosuvastatin, atrovastatin, psSk-9 inhibitor(relationship of blood ANGPTL, Sortilin, miRNA and so on level) (PIONEERs in Saitama Study 3)